Back to News
Market Impact: 0.35

Knight Therapeutics Reports Second Quarter 2026 Results

Corporate Guidance & OutlookCompany FundamentalsCorporate Earnings

The company raised 2026 guidance, now expecting revenue of $540 million to $560 million. It reported six-month record-high revenue of $293 million and Adjusted EBITDA of $52 million, supporting the improved outlook.

Analysis

The company raised 2026 guidance, now expecting revenue of $540 million to $560 million. It reported six-month record-high revenue of $293 million and Adjusted EBITDA of $52 million, supporting the improved outlook.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Demo

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.35

More News